Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multicen...
Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multicen...
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) (PERMIN)
Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multicen...
Statut
Status :
Terminé
Type d'étude
Phase IV
Age Min.
45
Ans
Age Max.
85
Ans
Genre
Homme
Aire thérapeutique :
Urologie
Maladie :
Hypertrophie bénigne de la prostate (HBP)
Traitement :
Permixon®
Phase :
Phase IV
Date de début de l'étude :
27 Juin 2012
End date :
08 Octobre 2013
Identifiant de l'essai :
P00048 GP 403
Identifiant EudraCT/CTIS :
2011-005307-33
Identifiant CT.gov :
NCT01604811
Envoyer par email